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Abstract
Despite the introduction of many novel therapeutics in clinical practice, metastatic renal cell carcinoma (RCC) remains a treatment-re-
sistant cancer. As red and processed meat are considered risk factors for RCC, and a vegetable-rich diet is thought to reduce this risk, 
research into plant-based therapeutics may provide valuable complementary or alternative therapeutics for the management of RCC. 
Herein, we present the antiproliferative and antiangiogenic effects of maslinic acid, which occurs naturally in edible plants, particularly 
in olive fruits, and also in a variety of medicinal plants. Human RCC cell lines (ACHN, Caki-1, and SN12K1), endothelial cells (human 
umbilical vein endothelial cell line [HUVEC]), and primary cultures of kidney proximal tubular epithelial cells (PTEC) were treated 
with maslinic acid. Maslinic acid was relatively less toxic to PTEC when compared with RCC under similar experimental conditions. In 
RCC cell lines, maslinic acid induced a significant reduction in proliferation, proliferating cell nuclear antigen, and colony formation. 
In HUVEC, maslinic acid induced a significant reduction in capillary tube formation in vitro and vascular endothelial growth factor. 
This study provides a rationale for incorporating a maslinic acid–rich diet either to reduce the risk of developing kidney cancer or as an 
adjunct to existing antiangiogenic therapy to improve efficacy.
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Introduction
Renal cell carcinoma (RCC) is a highly metastatic, hetero-
geneous disease that is resistant to conventional treatment 
modalities. In the past decade, the introduction of many 
novel targeted therapeutics, mostly tyrosine kinase inhibitors 
(TKIs) targeting the angiogenesis pathway, has  marginally 
increased progression-free and overall survival rates (1, 2). 
Resistance to therapy continues to be a major challenge in 
the effective treatment of metastatic RCC patients (3, 4). 
About 30% of patients are inherently resistant to TKIs, and 
the remaining 70% who initially respond to treatment even-
tually develop resistance (5–7). There is an immense need to 
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find novel anticancer agents to combat this deadly disease. 
The contribution of plant-derived natural products to cancer 
therapy has been widely acknowledged (8). The best exam-
ples are the taxanes paclitaxel and docetaxel, derived from 
the genus Taxus (9).
Research into plant-based potential alternative or comple-
mentary therapies is particularly important given that red and 
processed meat are thought to be risk factors for the develop-
ment of RCC (10–12) and that a vegetable-rich diet is consid-
ered to reduce the risk (13, 14). Maslinic acid is a pentacyclic 
triterpenoid that occurs naturally in edible plants, particularly 
in olive fruits, and also in a variety of medicinal plants (15, 16). 
Maslinic acid has been shown to have antioxidant (17), 
anti-inflammatory (18), antimalarial (19), antiprotozoan (20), 
antidiabetic (21), and anti–HIV-1 activities (22). In addition, 
in vitro, maslinic acid has been shown to exert proapoptotic 
effects on many human cancer cell lines including colon (15), 
prostate (23), bladder (24), and lung (25). The predominant 
mechanism appears to be induction of apoptosis through 
the inhibition of various antiapoptotic molecules including 
nuclear factor-κB and the antiapoptotic Bcl-2 family mem-
bers (15, 26). To our knowledge, the effect of maslinic acid on 
RCC has not been reported. In the current study, we explored 
the anticancer and antiangiogenic effects of maslinic acid in 
RCC cell lines and endothelial cells, respectively. Maslinic 
acid exerted significant anticancer and antiangiogenic prop-
erties. The major mechanism appears to be inhibition of pro-
liferation rather than induction of apoptosis.
Materials and Methods
Ethics approval
Approvals for the collection and use of primary cultures of 
human proximal tubular epithelial cells were obtained from 
the Human Research Ethics Committee of the Princess Alex-
andra Hospital and the Human Ethics Committee of University 
of Queensland, Brisbane, Australia. Written informed consent 
was obtained from patients before the collection of samples.
Cells and compounds
Maslinic acid (>98% purity) was purchased from Sigma- 
Aldrich (St. Louis, MO; Cat No. M6699-5MG). Maslinic 
acid was dissolved in dimethyl sulfoxide (DMSO) and further 
diluted in cell culture medium to the desired concentration. 
The compound was freshly prepared immediately before use. 
The human RCC cell lines ACHN and Caki-1, and the human 
umbilical vein endothelial cell (HUVEC) line were obtained 
from ATCC. Another human metastatic RCC cell line, 
SN12K1, was obtained from Professor D. Nicol, formerly at 
Princess Alexandra Hospital, Brisbane, Australia, through his 
collaborations with Dr I. J. Fidler, Cancer Research Institute, 
MD Anderson Cancer Center, Orlando, FL. Primary cultures 
of morphologically normal human kidney proximal tubular 
epithelial cells (PTECs) were isolated and maintained as per 
our previous publication (27). The RCC cell lines were main-
tained as a monolayer in DMEM/F12 (Gibco; Invitrogen, 
Carlsbad, CA) containing 10% fetal bovine serum (Gibco; 
Invitrogen, Carlsbad, CA) supplemented with 50-U/ml pen-
icillin and 50-µg/ml streptomycin, at 37°C in a humidified 
atmosphere of 5% CO
2
/95% air.
MTT Assay for Cell Viability
Cell viability in response to maslinic acid treatment was ana-
lyzed as per our previous report (28). In brief, 3 × 103 cells 
per well per 100 µl were seeded in 96-well culture plates and 
incubated for 24 hours. The cells were treated with various 
concentrations of maslinic acid, and after 24 hours of incu-
bation, 5 µl of MTT, from a stock of 5 mg/ml in phosphate 
buffered saline (PBS), was added to each well and incubated 
for 90 minutes at 37°C in a humidified atmosphere of 5% 
CO
2
/95% air. After the incubation period, the culture medium 
was removed and the purple crystals formed were dissolved 
in 100 µl of DMSO. The absorbance was recorded using a 
microplate reader at 570 nm with a reference wavelength of 
690 nm. The IC
50
 values were calculated from the absorbance.
Assessment of Apoptosis and Proliferation
Morphological assessment of apoptosis and proliferation 
was performed as per previous publication (28). In brief, 
5 × 104 cells were seeded on a cover slip in 24-well culture 
plates. After 24 hours, cells were treated with their respective 
IC
50
 values of maslinic acid. After an incubation period of 
24 hours, the culture medium was removed, and cells were 
fixed with 4% formalin. Hematoxylin and eosin staining was 
performed to study the morphology of proliferating cells and 
apoptotic cells. The cells were viewed under a 40× micro-
scope objective, and the cells that fell within the 100 squares 
of an eye graticule were counted. Apoptotic nuclei were 
determined based on their distinct morphological features: 
hyperchromasia, shrunken/ condensed nuclei, blebbing of the 
membrane while maintaining membrane integrity, crescent 
nuclei, and apoptotic bodies (29). Proliferating cells were 
identified by the conspicuous visibility of chromosomes, 
various stages of mitosis with a visible metaphase plate, and 
cytokinesis. Apoptotic and proliferating cells were expressed 
as a percentage of the total cells counted from five random 
fields for each cover slip.
Colony formation assay
Colony formation assay of RCC cell lines was performed as 
per our previous publication (30). Briefly, 1 × 103 RCC cells 
were seeded in six-well plates. Three hours later, the culture 
medium was removed and the plates were washed with culture 
medium to remove unattached cells. The cells were incubated 
in culture medium with or without maslinic acid and cultured 
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for 10 days. The medium was removed at the end of experi-
ments, the cells were washed in PBS, fixed in 4% formalin, 
washed in PBS, and stained with 0.5% crystal violet aqueous 
stain. The cells were washed until no stain came out, air dried, 
and photographed. The dye was extracted using DMSO and 
then quantified using a spectrophotometer at 590 nm.
In vitro angiogenesis
An in vitro angiogenesis assay was performed as described 
previously (31). Briefly, 96-well plates were coated with 50 µl 
of Matrigel (BD Biosciences, North Ryde, NSW, Australia) 
and allowed to solidify for 60 minutes at 37°C. HUVEC 
were dispersed in culture medium with or without maslinic 
acid (24 µM, which is half the IC
50
 value for HUVEC). The 
cells were then seeded on the Matrigel at a density of 3 × 104 
cells/100 µl. After 6 hours, the cells were photographed 
under a phase-contrast microscope. The number of tubes and 
the average length of tube per field were determined.
Gene expression studies
Cells were grown to approximately 90% confluence in 6-cm 
petri dishes and treated with or without maslinic acid. Twenty- 
four hours later, total RNA was isolated using PureLink RNA 
Mini Kit (Life Technologies, VIC, Australia) as per the man-
ufacturer’s protocol and quantified with Nano drop (Thermo 
Fisher Scientific, VIC, Australia). cDNA was synthesized using 
a High Capacity cDNA Reverse Transcription Kit (Life Tech-
nologies). In brief, 1 µg of RNA in a RT-PCR reaction mixture 
(2 µl 10× buffer, 0.8 µl dNTP, 2 µl r-hex, 1 µl enzyme, water to 
20 µl per reaction) was subjected to the following PCR con-
ditions: 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 
5 minutes followed by holding at 4°C. The cDNA was diluted 
to 50 µl with 30 µl of RNAse-free water. Fully  validated 
TaqMan Gene Expression Assay (Life Technologies) for vas-
cular endothelial growth factor A (VEGFA; Hs00900055_
m1), interleukin-6 (IL-6; Hs00985639_m1), interleukin-8 
(IL-8; Hs00174103_m1), proliferating cell nuclear antigen 
(PCNA; Hs00427214_g1), Bcl2-associated X protein (BAX; 
Hs00180269_m1), B-cell lymphoma 2 (Bcl2; Hs00236808_
s1), and tight junction protein 1 (TJP-1; Hs01551861_m1) 
was used with SensiFAST™ Probe No-ROX Kit (Bioline, 
London, UK) in a LightCycler 480 (Roche Applied Science, 
Penzberg, Germany) to determine relative gene expression 
by the comparative Ct method. The TATA box binding pro-
tein (TBP Hs00427620_m1; Life Technologies) was used as 
internal control, and for normalization.
Statistical analyses
The data were analyzed using Student’s t-test, and P < 0.05 
was considered significant. The experiments were performed 
in duplicates with n = 6 for each set. The results are expressed 
as mean ± standard error.
Results
Maslinic acid is toxic to RCC cell lines
The IC
50
 values of the RCC cell lines and PTEC, after 
24 hours of treatment with maslinic acid, are shown in Table 1. 
Of the three RCC cell lines, SN12K1 was the most suscep-
tible with an IC
50
 value of 47.11 µM and ACHN was the 
most resistant with an IC
50
 value of 76.52 µM. As toxicity 
is one of the major limiting factors in conventional chemo-
therapy, it was essential to test the toxicity of maslinic acid 
in noncancerous, morphologically normal proximal tubular 
cells. As expected, PTEC from nine donors showed varying 
responses. Although all PTEC showed a higher IC
50
 value than 
SN12K1, demonstrating selective toxicity of maslinic acid to 
this cell RCC cell type, five of nine PTEC (PTEC 4, 6, 7, 8, 
and 9) showed a higher IC
50
 value than ACHN and Caki-1. 
Thus, maslinic acid is relatively less toxic to PTEC when 
compared with RCC under similar experimental conditions. 
For further experiments, the respective IC
50
 values of each 
RCC cell lines were used.
Maslinic acid did not induce apoptosis  
in RCC cell lines
To find the mechanism of maslinic acid–induced cytotoxic-
ity, the proapoptotic effect of maslinic acid on the RCC cells 
was studied. After 24 hours of treatment, maslinic acid did 
not induce any significant changes in apoptosis (Figure 1A). 
To further confirm these findings at a molecular level, 
expression of the antiapoptotic gene Bcl2 and the proap-
optotic gene Bax was studied by validated human TaqMan 
Table 1.  IC
50
 values of cells
Cell Line IC
50
 (µM)
ACHN 76.52 ± 3.45
Caki-1 67.14 ± 1.02
SN12K1 47.11 ± 2.86
PTEC 1 60.16 ± 4.82
PTEC 2 65.83 ± 5.70
PTEC 3 66.50 ± 5.02
PTEC 4 97.04 ± 6.28
PTEC 5 63.17 ± 2.77
PTEC 6 88.90 ± 5.19
PTEC 7 92.50 ± 2.84
PTEC 8 85.50 ± 3.60
PTEC 9 89.80 ± 2.90
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primers. No significant changes in the expression of Bcl2 
(Figure 1B) or Bax (Figure 1C) were observed in response to 
maslinic acid treatment.
Maslinic acid decreased the proliferation  
of RCC cell lines
To further verify the mechanisms of maslinic acid–induced 
cytotoxicity, the antiproliferative activity of maslinic acid 
was studied. A significant decrease in proliferation of RCC 
cells was observed in response to maslinic acid (Figure 2A). 
A representative area from untreated cells and cells treated 
with maslinic acid is demonstrated (Figure 2B). To further 
confirm these findings at the molecular level, the expression 
of PCNA was studied by quantitative PCR using validated 
primers. A significant decrease in PCNA was observed in 
cells treated with maslinic acid (Figure 2C). Thus, the main 
mechanism of maslinic acid–induced cytotoxicity appears to 
be inhibition of proliferation rather than induction of apopto-
sis or cell death.
Figure 1. Lack of effect of maslinic acid on apoptosis and apoptosis-regulatory molecules. The effect of maslinic acid on apoptosis 
of RCC was studied 24 hours after incubating the cells with maslinic acid. Morphologically, maslinic acid did not induce any significant 
changes in apoptosis (A). These results were further confirmed at the molecular level by the lack of significant changes in the expression 
of the antiapoptotic molecule Bcl-2 (B), and the proapoptotic molecule Bax (C). U: untreated; T: treated with maslinic acid.
Figure 2. Maslinic acid significantly reduced the proliferation of RCC cells. Twenty-four hours after treatment, maslinic acid induced 
a significant reduction in proliferation of all three RCC cell lines (A). Representative images of untreated cells and cells treated with 
maslinic acid are demonstrated in B. Arrows highlight proliferating cells. At the molecular level, maslinic acid significantly reduced the 
expression of PCNA (C).*P < 0.05; **P < 0.01, and ***P < 0.001. U: untreated; T: treated with maslinic acid.
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Maslinic acid inhibited colony formation
Once a cell has detached from a primary tumor, it must attach 
to a distant part of the body to grow and metastasise. The col-
ony formation assay is one of the measures to study adhesion. 
Maslinic acid induced a significant decrease in colony for-
mation of ACHN, Caki-1, and SN12K1 cell lines (Figure 3). 
The number of colonies in the treated and nontreated 
groups appeared similar although the size of the colonies 
was smaller in the treated groups, further confirming the 
antiproliferative effect of maslinic acid. Quantification of 
the dye showed a significant decrease in cells treated with 
maslinic acid (graphs on the right side beside each photo-
Figure 3. Maslinic acid significantly reduced colony formation. Adhesion and colony formation are essential steps in distant metasta-
sis. Maslinic acid significantly decreased colony formation of all three cell lines. Left, representative images showing colony formation. 
Right, quantification of the dye. **P < 0.01; ***P < 0.001. C: untreated control; T: treated with maslinic acid.
Figure 4. Lack of effect of maslinic acid on markers of RCC progression. Analysis of TJP-1 (A), the IL-6 (B), IL-8 (C), and VEGF 
(D) did not show any significant changes in response to maslinic acid. These results further confirm that the primary effect of maslinic 
acid on RCC cell lines is inhibition of proliferation. U: untreated; T: treated with maslinic acid.
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graph). Analysis of some of the molecular markers, TJP-1 
(Figure 4A), IL-6 (Figure 4B), IL-8 (Figure 4C), and VEGF 
(Figure 4D), implicated in adhesion and metastasis, showed 
no significant changes between the control and treatment 
groups.
Maslinic acid inhibited in vitro angiogenesis
The antiangiogenic activity of maslinic acid was studied 
using an in vitro tube formation assay in HUVEC. Maslinic 
acid significantly decreased tube formation of HUVEC (Fig-
ure 5A and B). Quantification showed a significant decrease 
in the number (Figure 5C) and the length (Figure 5D) of 
tubes. To verify that the observed effect of maslinic acid was 
antiangiogenesis per se, not cell death, an MTT assay was per-
formed. For this, HUVEC were dispersed in culture medium 
with or without maslinic acid (24 µM). The cells were then 
seeded on 96-well plates at a density of (3 × 104 cells/100 µl). 
After 6 hours, the MTT assay was performed as described 
previously. No significant death of HUVEC was observed 
(Figure 5E), confirming independent antiangiogenic activity. 
To elucidate the molecular mechanism, the expression VEGF 
was studied. A significant decrease in VEGF was observed in 
response to maslinic acid (Figure 5F).
Discussion
Despite the introduction of many targeted therapies in the 
past decade, metastatic RCC continues to be a treatment- 
resistant malignancy. A need exists for the identification of 
more effective novel therapeutics. Plant-based natural com-
pounds as anticancer agents have been a subject of intense 
research and have produced some positive outcomes in the 
Figure 5. Maslinic acid inhibited in vitro angiogenesis. HUVEC in the untreated group formed enclosed network like structures (A), 
which was prevented by maslinic acid (B). Average number of tubes per field (C) and tube length (D) expressed as percentage in relation 
to control, are shown. Maslinic acid did not induce significant changes in viability of HUVEC (E), which confirms that the antiangio-
genic activity of maslinic acid is independent of its cytotoxicity. F, Maslinic acid decreased the expression of VEGF in endothelial cells. 
*P < 0.05 and ***P < 0.001.
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past as exemplified by the taxanes (9). Herein, we studied 
the anticancer effect of maslinic acid, a naturally occurring 
pentacyclic triterpenoid found abundantly in olives and 
many other plants (16), with emphasis on apoptosis and 
proliferation of RCC cell lines and angiogenesis of endothe-
lial cells.
A defective apoptotic pathway is one of the hallmarks of 
cancer (32) and is thought to regulate cancer biology by at 
least two mechanisms: failure to remove aberrant cells and 
providing resistance to chemotherapy. The two major path-
ways of apoptosis regulation are the extrinsic or the death- 
receptor pathway, and the intrinsic or the mitochondrial 
pathway (33, 34). The extrinsic pathway induces apoptosis 
through cleavage of caspase, whereas the intrinsic pathway 
exerts apoptosis through the modulation of the Bcl2 family of 
apoptosis-regulatory molecules (34). The proapoptotic effect 
of maslinic acid has been extensively studied in many cancer 
cells. Some of the reported mechanisms include the downreg-
ulation of the antiapoptotic Bcl2 molecules and inhibitor of 
apoptosis proteins and the upregulation of the proapoptotic 
molecules such as Bax, cleaved caspase-3, caspase-8, and 
caspase-9 (15, 35). In our study, contrary to the proapoptotic 
effect reported for other cancer cells, maslinic acid did not 
demonstrate any significant proapoptotic effects, either mor-
phologically or at molecular level. To further investigate the 
mechanism of action maslinic acid, we focused on the effect 
on proliferation.
Maslinic acid induced a significant decrease in prolifer-
ation of the RCC cells: morphologically by a lower number 
of mitotic cells, reduced size of colonies, and molecularly 
by decreased PCNA expression. PCNA plays a crucial role 
in cell cycle and proliferation by appearing in the nucleus 
during the late G1 phase, increasing during the S phase, 
and decreasing during the G2 and M phases (36). RCC is a 
highly metastatic disease, and a higher expression of PCNA 
is thought to be an indicator of unfavorable prognosis (37). 
Expression of PCNA is associated with the expression of 
epidermal growth factor receptor, which itself is a survival 
factor for many cancers, including RCC. PCNA is also asso-
ciated with the MYC pathway and is the target molecule of 
pro-oncogenic MYC. Knockdown of MYC has been shown 
to suppress the proliferation of clear cell RCC (38). Thus, 
maslinic acid may directly inhibit RCC progression via the 
reduction of PCNA and indirectly by reducing the substrate of 
other oncogenic molecules. The expression pattern of TJP-1, 
IL-6, IL-8, and VEGF, some of the most studied molecules 
that are well-known players in RCC progression, showed no 
significant changes in response to maslinic acid.
After verifying that the mechanism of action of maslinic 
acid is mediated via the inhibition of proliferation rather 
than the induction of apoptosis, we explored its antiangio-
genic actions. Due to aberrations in von Hippel Lindau gene, 
and subsequent activation of downstream hypoxia-inducible 
proangiogenic factors, RCC is one of the most vascularized 
Figure 6. Putative role of maslinic acid on proliferation and angiogenesis. Aberrations of von Hippel-Lindau gene (VHL) are the 
major risk factors for RCC. Inactivated VHL leads to the upregulation of hypoxia-inducible factor (HIF), which in turn leads to the 
upregulation of many molecules that promote RCC progression through enhanced angiogenesis and proliferation. Maslinic acid inhibits 
angiogenesis and proliferation possibly via the downregulation of VEGF in vascular endothelial cells and PCNA in RCC. Emphasis is 
given to molecules of interest from this study.
Maslinic Acid Inhibits Proliferation of RCC
Journal of Kidney Cancer and VHL 2017;4(1):16–24 23
solid tumors (39). The majority of the targeted therapies 
introduced in clinical practice in the past decade are multi- 
TKIs, targeting the angiogenesis pathway (40). In vitro cap-
illary tube formation assay showed that maslinic acid has 
antiangiogenic effects independent of its cytotoxic effects. At 
the molecular level, it significantly inhibited VEGF, the prime 
mediator of angiogenesis. VEGF expression has a correlation 
with tumor microvascular density, disease progression, and 
metastasis of RCC (41–43).
In summary, maslinic acid exerts antiproliferative and 
antiangiogenic activities. The putative mechanisms of action 
of maslinic acid, based on our results, are summarized in 
Figure 6. Our results on antiangiogenic and antiprolifera-
tive activities are in line with previously published reports of 
maslinic acid (23–26, 44) and other pentacyclic triterpenoic 
acids such as ursolic acid and oleanolic acid (44–47). It is 
well known that tumor type is a determinant of susceptibility 
to apoptosis (48) and that compounds can exert cell-specific 
apoptosis (49). We believe that this may be a reason why 
maslinic acid did not induce apoptosis in RCC cells.
In conclusion, this study provides a rationale for incor-
porating a maslinic acid–rich diet either to reduce the risk of 
developing kidney cancer or as an adjunct to existing antican-
cer therapy, particularly antiangiogenic therapies, to improve 
efficacy. Considering the need for alternative and comple-
mentary therapies for RCC, further studies are warranted to 
explore the antiproliferative and antiangiogenic potential of 
maslinic acid as a therapeutic agent for RCC.
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